Sylvester investigators identify potential targets to overcome treatment resistance in TNBC

NBCC’s open letter to Ways and Means demands markup for Metastatic Breast Cancer Access to Care Act

NBCC President Fran Visco authored the following open letter to the House Ways and Means Committee, criticizing the committee for failing to bring the Metastatic Breast Cancer Access to Care Act, HR 2048, before the committee for markup.

Sylvester’s Marlon Wong receives Gabrielle’s Angel Foundation grant to study CIPN

Marlon L. Wong, associate professor of clinical physical therapy at the University of Miami Miller School of Medicine, was awarded a grant from Gabrielle’s Angel Foundation for Cancer Research. The three-year, $225,000 award will support research focused on improving quality of life for patients living with chemotherapy-induced peripheral neuropathy and other long-term effects of cancer treatment.

July 24, 2026

Vol.52 No.29

Clinical Roundup

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Breast cancers diagnosed during the first three years after childbirth, particularly within the first year, may be biologically more aggressive than similar cancers in women who have never given birth, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

July 10, 2026

Vol.52 No.27

Clinical Roundup

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

For people at high risk of developing breast cancer, yearly mammograms may not be enough to detect tumors early. To make earlier diagnosis easier, a Massachusetts Institute of Technology team has developed portable detectors based on ultrasound, which could be used much more frequently. The team reports that they have improved the resolution of the images produced by their system, making it easier to spot potential tumors, as well as cysts and microcalcifications.

July 10, 2026

Vol.52 No.27

Clinical Roundup

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

MammaPrint + BluePrint can help identify a subset of patients with hormone receptor positive, HER2-negative early-stage breast cancer most likely to benefit from anthracycline-based chemotherapy, according to the results of the prospective FLEX Study (NCT03053193).

July 02, 2026

Vol.52 No.26

Drugs & Targets

FDA approves Trodelvy for first-line treatment of mTNBC

FDA approved Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate, for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer.

July 02, 2026

Vol.52 No.26

Sylvester investigators identify potential targets to overcome treatment resistance in TNBC

YOU MAY BE INTERESTED IN

NBCC’s open letter to Ways and Means demands markup for Metastatic Breast Cancer Access to Care Act

Sylvester’s Marlon Wong receives Gabrielle’s Angel Foundation grant to study CIPN

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

FDA approves Trodelvy for first-line treatment of mTNBC

Renew today!

Subscriber content

Never miss an issue!

Login